CAREERS
Working at Risen
Job opportunities
Employee welfare
繁体
简体
Pipeline Code
Target
Modality
Indication
IND-Enabling
Phase Ⅰ
Phase II/III
Partners
Pipeline Code
Target
Modality
Indication
Lead ID
Lead Optimization
PCC
IND-Enabling
Partners
Product pipeline
Clinical
Discovery
Pipeline Code
Target
Modality
Indication
IND-Enabling
Phase I
Phase II/III
Partners
RP901
General
Small Molecule
OA
OA
RP901 is a small molecule innovative drug discovered and developed by Risen. After oral administration, RP901 can be rapidly transformed in vivo to protect bone and improve the symptoms of osteoarthritis, and is used for the treatment of osteoarthritis (OA). OA is a degenerative disease with joint pain as the main symptom caused by multiple factors such as joint cartilage fibrosis, chapping, ulcer and loss.
RP901
preclinical
IND
Phase I
Phase II/III

Target :General

Modality :Small Molecule

Indication :OA

Partners:

RP901 is a small molecule innovative drug discovered and developed by Risen. After oral administration, RP901 can be rapidly transformed in vivo to protect bone and improve the symptoms of osteoarthritis, and is used for the treatment of osteoarthritis (OA). OA is a degenerative disease with joint pain as the main symptom caused by multiple factors such as joint cartilage fibrosis, chapping, ulcer and loss.
RP902
Amyloid-β
Small Molecule
Alzheimer's Disease （AD）
Alzheimer's Disease （AD）
RP902 is A stable isotope substituted small molecule innovative drug discovered and developed by Risen, which takes β-Amyloid (Aβ) as the main target for the treatment of Alzheimer's disease (AD).
RP902
preclinical
IND
Phase I
Phase II/III

Target :Amyloid-β

Modality :Small Molecule

Indication :Alzheimer's Disease （AD）

Partners:

RP902 is A stable isotope substituted small molecule innovative drug discovered and developed by Risen, which takes β-Amyloid (Aβ) as the main target for the treatment of Alzheimer's disease (AD).
RP903
PI3Kα
Small Molecule
Cancer
Cancer
RP903 is a stable isotope replacement small molecule innovative drug discovered and developed by Risen. It is a selective small molecule inhibitor targeting PI3Kα, which is used for the treatment of advanced malignant solid tumors with PIK3CA mutation.
RP903
preclinical
IND
Phase I
Phase II/III

Target :PI3Kα

Modality :Small Molecule

Indication :Cancer

Partners:

RP903 is a stable isotope replacement small molecule innovative drug discovered and developed by Risen. It is a selective small molecule inhibitor targeting PI3Kα, which is used for the treatment of advanced malignant solid tumors with PIK3CA mutation.
RP912
ANGPTL3
siRNA
Metabolic Diseases
Metabolic Diseases
RP912 is the first siRNA drug for ANGPTL3 in China jointly developed by Risen and TopAlliance, which uses the GalNAc delivery system with independent intellectual property rights, and will be used for the treatment of hypertriglyceridemia and hypercholesterolemia, as well as cardiovascular diseases caused by dyslipidemia.
RP912
preclinical
IND
Phase I
Phase II/III

Target :ANGPTL3

Modality :siRNA

Indication :Metabolic Diseases

Partners:

RP912 is the first siRNA drug for ANGPTL3 in China jointly developed by Risen and TopAlliance, which uses the GalNAc delivery system with independent intellectual property rights, and will be used for the treatment of hypertriglyceridemia and hypercholesterolemia, as well as cardiovascular diseases caused by dyslipidemia.
RP910
PCSK9
siRNA
Metabolic Diseases
Metabolic Diseases
RP910 is a PCSK9-targeting siRNA drug jointly developed by Risen and TopAlliance, which uses the GalNAc delivery system with independent intellectual property rights, and will be used to treat dyslipidemia and cardiovascular diseases caused by dyslipidemia.
RP910
preclinical
IND
Phase I
Phase II/III

Target :PCSK9

Modality :siRNA

Indication :Metabolic Diseases

Partners:

RP910 is a PCSK9-targeting siRNA drug jointly developed by Risen and TopAlliance, which uses the GalNAc delivery system with independent intellectual property rights, and will be used to treat dyslipidemia and cardiovascular diseases caused by dyslipidemia.
RP913
KRASG12D
PROTAC
Cancer
Cancer
RP913 is a new molecular entity discovered and developed by Risen. It is a selective PROTAC (Proteolytic targeting chimera) targeting KRASG12D for the treatment of malignant solid tumors with KRASG12D mutation.
RP913
preclinical
IND
Phase I
Phase II/III

Target :KRASG12D

Modality :PROTAC

Indication :Cancer

Partners:

RP913 is a new molecular entity discovered and developed by Risen. It is a selective PROTAC (Proteolytic targeting chimera) targeting KRASG12D for the treatment of malignant solid tumors with KRASG12D mutation.
Pipeline Code
Target
Modality
Indication
Lead ID
Lead Optimization
PCC
IND-Enabling
Partners
RJ010
Pending disclosure
siRNA
Autoimmune Diseases
RJ010
Lead ID
Lead Optimization
PCC
IND-Enabling

Target :Pending disclosure

Modality :siRNA

Indication :Autoimmune Diseases

Partners:

RJ011
Pending disclosure
siRNA
metabolic diseases
RJ011
Lead ID
Lead Optimization
PCC
IND-Enabling

Target :Pending disclosure

Modality :siRNA

Indication :metabolic diseases

Partners:

RJ007
Pending disclosure
small molecule
cancer
RJ007
Lead ID
Lead Optimization
PCC
IND-Enabling

Target :Pending disclosure

Modality :small molecule

Indication :cancer

Partners:

RJ014
Pending disclosure
PROTAC
cancer
RJ014
Lead ID
Lead Optimization
PCC
IND-Enabling

Target :Pending disclosure

Modality :PROTAC

Indication :cancer

Partners:

RJ008
Pending disclosure
small molecule
cancer
RJ008
Lead ID
Lead Optimization
PCC
IND-Enabling

Target :Pending disclosure

Modality :small molecule

Indication :cancer

Partners:

RJ017
Pending disclosure
ASO
Autoimmune Diseases
RJ017
Lead ID
Lead Optimization
PCC
IND-Enabling

Target :Pending disclosure

Modality :ASO

Indication :Autoimmune Diseases

Partners:

RJ018
Pending disclosure
siRNA
metabolic diseases
RJ018
Lead ID
Lead Optimization
PCC
IND-Enabling

Target :Pending disclosure

Modality :siRNA

Indication :metabolic diseases

Partners:

RJ019
Pending disclosure
siRNA
metabolic diseases
RJ019
Lead ID
Lead Optimization
PCC
IND-Enabling

Target :Pending disclosure

Modality :siRNA

Indication :metabolic diseases

Partners:

RJ020
Pending disclosure
siRNA
cancer
RJ020
Lead ID
Lead Optimization
PCC
IND-Enabling

Target :Pending disclosure

Modality :siRNA

Indication :cancer

Partners:

Shanghai Zhangjiang R&D Center.
Suzhou Industrial Park R&D Center.
Shanghai Lingang Industrial Base.
send mail
Copyright 2022 Risen(Shanghai) Pharma Tech Co., Ltd. All Rights Reserved 沪ICP备16020731号-1 Design by：yushangweb